^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TBX21 expression

    i
    Other names: TBX21, T-Box Transcription Factor 21, T-Cell-Specific T-Box Transcription Factor T-Bet, T-Box Transcription Factor TBX21, Transcription Factor TBLYM, T-Box Protein 21, T-Box 21, TBLYM, TBET, T-Box Expressed In T Cells, T-PET, T-Bet
    Entrez ID:
    30009
    Related biomarkers:
    Expression
    1year
    TBX21 attenuates colorectal cancer progression via an ARHGAP29/RSK/GSK3β dependent manner. (PubMed, Cell Oncol (Dordr))
    In summary, the aforementioned findings suggest a model of TBX21 in suppressing CRC progression. This may provide a promising target for CRC therapy.
    Journal
    |
    TBX21 (T-Box Transcription Factor 21) • GSK3B (Glycogen Synthase Kinase 3 Beta)
    |
    TBX21 expression
    over1year
    TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer. (PubMed, Cancers (Basel))
    Further analysis using pathway enrichment found that the genes TBX21, MX1, and SP140 had altered expression and methylation, suggesting that the TP53/P53 pathway may modify TBX21 methylation to upregulate TBX21 expression. Together, this suggests that targeting epigenetic modification more specifically for therapy and patient stratification may provide improved outcomes in CRC.
    Journal • IO biomarker
    |
    TBX21 (T-Box Transcription Factor 21) • MX1 (MX Dynamin Like GTPase 1)
    |
    TBX21 expression
    over3years
    [VIRTUAL] Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy (ASH 2020)
    In particular, T cells composition (low CD4:CD8 ratio and reduced population of Tscm, Tcm) along with an enrichment of terminally exhausted T cells are the main features observed in resistant patients. Delineating these mechanisms will guide future T cells engineering studies to enhance the efficacy and response durability of adoptive immunotherapy in MM.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • TBX21 (T-Box Transcription Factor 21) • FAS (Fas cell surface death receptor) • GATA3 (GATA binding protein 3)
    |
    PD-1 expression • LAG3 expression • TBX21 expression